Adagrasib

CAS 2326521-71-3

Interested in hearing more about this API?

Adagrasib is a targeted therapy for cancers with KRAS G12C mutations, such as non-small cell lung cancer. It works by irreversibly inhibiting the mutant KRAS protein, which drives cancer cell growth. This precision medicine has shown promising efficacy in previously difficult-to-treat cancers.

About the API

Technology

Synthetic

Therapeutic category

Oncology

Systematic Name

2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources. For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.